Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.

We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.

In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.

If you need assistance finding or assessing business development and/or partnership opportunities, contact us at

Current Projects

China: Opportunities to Access Partnerships and Capital  
Posted on Feb 14, 2015


Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect to

  Read More»

Licensing Opportunity: Parenteral Diclofenac  
Posted on Mar 06, 2015


Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved parenteral formulation of diclofenac for acute / postoperative pain. While parenteral diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics. Key product benefits over the currently marketed product include:

  Read More»

Licensing Opportunity: Superior Topical Diclofenac Product  
Posted on Mar 06, 2015


Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved topical formulation of diclofenac for pain. While topical diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics. This topical diclofenac has a number of advantages over available topical diclofenac

  Read More»

Our Latest Article

Would Mefloquine Be Approved Today? 
Posted on Aug 25, 2015



As part of my preparations for an upcoming trip to India, my physician prescribed a 6-week prophylactic course of mefloquine to prevent malaria.

The weekly dosing schedule prompted me to review the package insert. As it turns out, mefloquine has an unusually high half-life (2-4 weeks), making it perfect for weekly dosing.

A review of the Wikipedia entry for mefloquine resulted in a few articles describing the history of this drug, and how it was developed.

According to Croft, mefloquine was compound number 142,490 out of over 250,000 chemical derivatives of chloroquine. Resistance to cholorquine was observed in the 1950s, and soldiers participating in the Vietnam War were succumbing to malaria at alarming rates.

This prompted a massive (at least by 1960’s standards) drug discovery program at the Walter Reed Army Institute of Research (WRAIR) to find effective preventatives and treatments for malaria.

WRAIA collaborated with 175 external contractors, an incredible number by 1960’s standards.

This effort also resulted in the discovery of halofantrine, which is chemically related to mefloquine.

The details are sketchy, but according to Croft, Phase I and Phase II clinical data were “transferred” to Roche and Smith Kline Beecham “as a free good.” Lariam (mefloquine) and Halfan (halofantrine) were eventually approved in 1989 and 1992, respectively.

Now the war was obviously long over by the time these two agents were approved, so their main markets were for travel prophylaxis. Yet, prior to FDA approval, no Phase III trials were conducted in healthy volunteers.

It wasn’t until 2001-2003 that randomized controlled trials were conducted in healthy populations, and the studies confirmed what many people already knew; that mefloquine has the potential for causing psychological and neuropsychological adverse effects.

Halofantrine was also unexpectedly (unexpected because it was never properly researched) found to have a number of serious side effects, to the point where it is no longer recommended by WHO for the self-treatment of malaria. 

Now if you read the article by Croft, you will note that the article delves into a criticism of the “military-industrial complex” which drove this “natural experiment” post-approval. To quote, 

Customers have been unwitting recruits to this longitudinal study, rather than informed partners…The rapid public rejection of Lariam and Halfan could have been anticipated, since users of malaria chemoprophylaxis differ from normal patients in that they are by definition healthy people, and on this account they are unwilling to accept even relatively minor drug-related harms.

Dr. Croft goes on to cite a number of cases where mefloquine might be implicated in a series of adverse drug events, including a series of murders and suicides amongst soldiers who served in Afghanistan. 

Dr. Croft does not mention the combination atovaquone-proguanil (Malarone, GSK), which has a better side effect profile and comparable efficacy compared with mefloquine. But, Dr. Croft does note that no manufacturer has the incentive to conduct additional studies. And, since better drugs are emerging, both mefloquine and halofantrine will eventually be “discarded.”

Dr. Croft concludes,

This apparent willingness to casually sideline two undoubtedly lifesaving drugs represents a waste of resources, and a loss also to future travellers and patients. Researchers, policy makers and prescribers must learn from this experience or be condemned to repeat it. Many of the individual medical tragedies detailed in the table need never have occurred. Powerful institutional pressures must never again override the needs and rights of patients.

Would Mefloquine Be Approved Today?

It’s hard to say if a drug like mefloquine would be approved today for any condition, let alone malaria prophylaxis. With 1% of Vietnam soldiers succumbing to malaria per day, it is somewhat understandable that the US government would make the significant effort to screen 250,000 compounds for a treatment. 

Interestingly, mefloquine may have some effectiveness against progressive multifocal leukoencephalopathy, a rare viral disease caused by the JC virus. PML occurs in patients who have secondary immune deficiency, such as AIDS, and also in the immunosuppressed (i.e., severe autoimmune disorders, transplant patients, etc.). 

Could these represent orphan indications for a drug like mefloquine today? Maybe. Maybe not. 

But what is clear is that the days of the FDA approving drugs without Phase III data (and arguably without sufficient Phase II studies) are long gone…at least we hope they are…

Latest Posts

Licensing or Acquiring Assets from Big Pharma 
Posted on Aug 12, 2015

  Michael Gilman, CEO of Padlock Therapeutics, wrote a terrific post recounting his experiences from in-licensing assets from Big Pharma. Mike’s perspective is unique in that he has managed to pull this off not once, but twice. It has been our experience that doing this once is incredibly difficult. But why? Mike gives a few

Global Formulation Report 
Posted on Jul 24, 2015

  The July/August issue of Drug Development and Delivery has an extensive report on the business and science of formulation and drug delivery. The report is based on the data in the PharmaCircle database.  The report is divided into various “Top Ten” categories, such as Ten Notable Drug Delivery Technologies of 2014, Transactions, etc., etc. 

What Is a “Good” Client? 
Posted on Jul 14, 2015

  This question came up recently when I was describing one of our current clients as a “good” client. But what exactly is a “good” client? Three things come to mind.  Responsiveness – There are many qualities that a good client possesses, but I think responsiveness comes to the top of the list, especially when we are

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.